N-Zyme Biomedical Inc.

03/06/2026

N-Zyme Biomedical is pleased to announce that the Japan Patent Office (JPO) has granted the Company a new patent covering the use of HIV protease inhibitors for the treatment of reflux disease.

N-Zyme Biomedical, a clinical-stage biopharmaceutical company focused on the development of innovative therapies for patients with reflux disease, including gastroesophageal reflux disease (GERD) and laryngopharyngeal reflux (LPR), has received patent approval for Japanese Patent No. 2022-563006, titled “Aerosolized Formulations of HIV Protease Inhibitors for the Treatment of Airway Reflux.”

The patent granted by the JPO strengthens N-Zyme’s intellectual property portfolio covering the use of fosamprenavir and darunavir for the treatment of reflux disease, underscoring the novelty and innovation driving the Company’s drug development programs.

“This patent marks an important milestone for N-Zyme. It reinforces the scientific innovation behind our pipeline and strengthens our ability to deliver transformative therapies for patients living with reflux disease.”

— Franco Vigile, Co-Founder and Chief Executive Officer, N-Zyme Biomedical

To learn more about what we’re doing to address a significantly unmet need within the reflux industry, please visit our website at: www.nzymebio.com

02/12/2026

N-Zyme’s Co-Founder and Chief Scientific Officer, Dr. Nikki Johnston, sits down with former U.S. Congressman Jason Lewis to discuss a groundbreaking therapy she and her team are developing for reflux disease. This innovative approach has the potential to transform treatment for millions of people worldwide affected by reflux, a condition that, if left untreated, can lead to serious health complications, including an increased risk of laryngeal cancer.

N-Zyme’s Co-Founder and Chief Scientific Officer, Dr. Nikki Johnston, sits down with former U.S. Congressman Jason Lewis to discuss a groundbreaking therapy ...

12/08/2025

N-Zyme is pleased to announce that, in addition to its transition to a Delaware corporation earlier this year, the Company has established a new corporate headquarters located at 1225 Discovery Parkway, Suite 260E, Wauwatosa, WI 53266.

The accompanying photos feature N-Zyme’s Chief Scientific Officer, Dr. Nikki Johnston, together with members of her laboratory team, working from the newly established facility.

“The past year has been marked by significant advancement across multiple areas of the organization, and we look forward to sharing comprehensive updates with our valued shareholders and supporters in the near future. We extend our sincere appreciation for your continued confidence, encouragement, and support as we advance our mission to pioneer innovative therapies within the complex reflux landscape and address a substantial unmet clinical need.”

-Franco Vigile, Co-Founder & CEO

07/10/2025

N-Zyme is pleased to welcome Brendan Hussey, Ph.D., to its advisory board.

Brendan is a trained Synthetic Biologist, exited biotech CSO/entrepreneur, former investment banker and current venture capitalist. Brendan has over 20 years experience across the deep tech biotechnology value creation chain from academic discovery through tech translation and capital markets.

See full bio here: https://www.nzymebio.com/team/brendan-hussey